JPMorgan Chase & Co. increased its holdings in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 15.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,831,951 shares of the medical instruments supplier’s stock after buying an additional 240,740 shares during the quarter. JPMorgan Chase & Co. owned 0.80% of DENTSPLY SIRONA worth $118,783,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. raised its stake in DENTSPLY SIRONA by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 22,165,069 shares of the medical instruments supplier’s stock worth $1,383,988,000 after buying an additional 584,536 shares during the period. BlackRock Inc. raised its stake in DENTSPLY SIRONA by 3,103.7% during the 1st quarter. BlackRock Inc. now owns 13,891,329 shares of the medical instruments supplier’s stock worth $867,376,000 after buying an additional 13,457,730 shares during the period. State Street Corp raised its stake in DENTSPLY SIRONA by 0.4% during the 1st quarter. State Street Corp now owns 9,931,689 shares of the medical instruments supplier’s stock worth $620,136,000 after buying an additional 36,012 shares during the period. Principal Financial Group Inc. raised its stake in DENTSPLY SIRONA by 22.3% during the 2nd quarter. Principal Financial Group Inc. now owns 6,474,432 shares of the medical instruments supplier’s stock worth $419,802,000 after buying an additional 1,181,547 shares during the period. Finally, Veritas Asset Management LLP raised its stake in DENTSPLY SIRONA by 2.6% during the 2nd quarter. Veritas Asset Management LLP now owns 6,201,155 shares of the medical instruments supplier’s stock worth $402,083,000 after buying an additional 157,616 shares during the period. 93.97% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “DENTSPLY SIRONA Inc. (XRAY) Shares Bought by JPMorgan Chase & Co.” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/08/dentsply-sirona-inc-xray-shares-bought-by-jpmorgan-chase-co.html.

Shares of DENTSPLY SIRONA Inc. (XRAY) opened at 57.83 on Friday. The firm’s market cap is $13.27 billion. The firm has a 50 day moving average price of $57.90 and a 200 day moving average price of $61.93. DENTSPLY SIRONA Inc. has a 1-year low of $52.53 and a 1-year high of $65.68.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings data on Wednesday, August 9th. The medical instruments supplier reported $0.65 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.65. The company had revenue of $992.70 million for the quarter, compared to analysts’ expectations of $1 billion. DENTSPLY SIRONA had a negative net margin of 20.57% and a positive return on equity of 7.24%. The business’s revenue was down 2.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.76 EPS. Analysts anticipate that DENTSPLY SIRONA Inc. will post $2.68 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 13th. Stockholders of record on Friday, September 29th will be given a dividend of $0.0875 per share. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $0.35 dividend on an annualized basis and a dividend yield of 0.61%. DENTSPLY SIRONA’s dividend payout ratio (DPR) is presently -10.09%.

Several brokerages recently commented on XRAY. HC Wainwright reaffirmed a “buy” rating and set a $68.00 price objective (down previously from $74.00) on shares of DENTSPLY SIRONA in a research note on Monday, August 14th. Credit Suisse Group reaffirmed an “outperform” rating and set a $75.00 price objective (up previously from $67.00) on shares of DENTSPLY SIRONA in a research note on Thursday, July 13th. BidaskClub raised DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a research note on Friday, June 30th. TheStreet downgraded DENTSPLY SIRONA from a “b” rating to a “c+” rating in a research note on Wednesday, August 9th. Finally, Morgan Stanley raised their price objective on DENTSPLY SIRONA from $66.00 to $67.00 and gave the stock an “overweight” rating in a research note on Thursday, August 10th. Three analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the stock. DENTSPLY SIRONA presently has a consensus rating of “Hold” and a consensus target price of $66.08.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY).

Institutional Ownership by Quarter for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Stock Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related stocks with our FREE daily email newsletter.